Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer

Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of NSCLC * Stage IIIb with pleural effusion, Stage IV, or recurrent disease * Measurable or evaluable disease by RECIST criteria * ECOG performance status 0-1 * Adequate hepatic/renal function and platelet count * If previously treated with an anthracycline, anthracenedione, or trastuzumab, must have left ventricular ejection fraction \> 50% Exclusion Criteria: * More than 2 prior chemotherapy regimens for metastatic disease (prior adjuvant chemotherapy is allowed) * Tumor progression during treatment with paclitaxel (refractory to paclitaxel) * Taxane-based regimen within 12 weeks * Any systemic therapy for cancer within 4 weeks * Anti-platelet therapy within 2 weeks, other than low dose aspirin prophylaxis therapy * Therapeutic anticoagulation therapy except for low dose warfarin (eg, 1 mg by mouth per day) * Radiation therapy within 3 weeks * Major surgery within 4 weeks (central line placement is allowed) * Prolongation of PT or aPTT \> the ULN or fibrinogen \< the LLN * History of or active central nervous system metastatic disease * Any other active malignancy * Active or chronically recurrent bleeding (eg, active peptic ulcer disease) * Clinically significant infection * Active autoimmune disease requiring immunosuppressive therapy * Clinically significant cardiovascular disease or condition